albuterol has been researched along with Parkinson Disease in 6 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The albuterol-treated patients demonstrated reduced parkinsonian symptoms and an increased ability to tap their index finger between two points 20 cm apart, and were able to perform a "walk test" in 70% of their control time." | 2.67 | Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease. ( Alexander, GM; Grothusen, JR; Hooker, MD; Nukes, TA; Schwartzman, RJ, 1994) |
| " Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract." | 1.51 | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. ( Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gillette, C | 1 |
| Cooney, JW | 1 |
| Sisson, CB | 1 |
| Rockich-Winston, N | 1 |
| Perry, CJ | 1 |
| Moore, WC | 1 |
| Mittal, S | 1 |
| Bjørnevik, K | 1 |
| Im, DS | 1 |
| Flierl, A | 1 |
| Dong, X | 1 |
| Locascio, JJ | 1 |
| Abo, KM | 1 |
| Long, E | 1 |
| Jin, M | 1 |
| Xu, B | 1 |
| Xiang, YK | 1 |
| Rochet, JC | 1 |
| Engeland, A | 1 |
| Rizzu, P | 1 |
| Heutink, P | 1 |
| Bartels, T | 1 |
| Selkoe, DJ | 1 |
| Caldarone, BJ | 1 |
| Glicksman, MA | 1 |
| Khurana, V | 1 |
| Schüle, B | 1 |
| Park, DS | 1 |
| Riise, T | 1 |
| Scherzer, CR | 1 |
| Fletcher, EJR | 1 |
| Jamieson, AD | 1 |
| Williams, G | 1 |
| Doherty, P | 1 |
| Duty, S | 1 |
| Alexander, GM | 1 |
| Schwartzman, RJ | 1 |
| Nukes, TA | 1 |
| Grothusen, JR | 1 |
| Hooker, MD | 1 |
| Martin, S | 1 |
| Hishida, R | 1 |
| Kurahashi, K | 1 |
| Narita, S | 1 |
| Baba, T | 1 |
| Matsunaga, M | 1 |
1 trial available for albuterol and Parkinson Disease
| Article | Year |
|---|---|
Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.
Topics: Aged; Albuterol; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
5 other studies available for albuterol and Parkinson Disease
| Article | Year |
|---|---|
Levodopa inhalation powder in a patient with persistent asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dopamine Agents; Dry Powder In | 2020 |
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.
Topics: Acetylation; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; alpha-Synu | 2017 |
Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.
Topics: Albuterol; Animals; Brain; Computer Simulation; Corpus Striatum; Dimethadione; Dopaminergic Neurons; | 2019 |
Pharmaceutical review: salbutamol - madopar - isocal.
Topics: Albuterol; Australia; Benserazide; Humans; Hydrazines; Levodopa; Lung Diseases; Parenteral Nutrition | 1978 |
"Wearing-off" and beta 2-adrenoceptor agonist in Parkinson's disease.
Topics: Aged; Albuterol; Brain; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Di | 1992 |